Sarepta Therapeutics to Host Webcast and Conference Call for the Duchenne
Muscular Dystrophy Community on October 17, 2013
CAMBRIDGE, MA -- (Marketwired) -- 10/10/13 -- Sarepta Therapeutics,
Inc. (NASDAQ: SRPT), a developer of innovative RNA-based
therapeutics, will host a webcast and conference call for the
Duchenne muscular dystrophy (DMD) community on Thursday, October 17,
2013, beginning at 12:00 p.m., Eastern Time (9:00 a.m., Pacific
Time). Chris Garabedian, president and chief executive officer, and
Edward Kaye, M.D., chief medical officer, will provide information
and answer questions about Sarepta's DMD development program,
including current and planned clinical trials, and Let's Skip Ahead,
a new online resource center from Sarepta for patients and families
available at www.skipahead.com.
Sarepta has invited DMD community representatives from leading
patient advocacy groups including Cure Duchenne, Duchenne Alliance,
Muscular Dystrophy Association and Parent Project Muscular Dystrophy
to participate in the question and answer portion of the webcast.
Patients and families who have questions about Sarepta's DMD
development program are encouraged to share them with any one of
these groups prior to the event.
To access the webcast, visit the events and presentations section of
Sarepta's website at www.sarepta.com/events and follow the link for
the webcast under "Upcoming Events." Please connect several minutes
prior to the start of the broadcast to ensure adequate time for any
software download that may be necessary.
To access only the audio portion, dial in to 1-888-895-5479 (toll
free) or 1-847-619-6250. The passcode for the call is 35883585.
Please specify to the operator that you would like to join the
"Sarepta DMD Development Program Update."
Following the event, the webcast will be archived in the events and
presentations section of Sarepta's website for 90 days.
About Sarepta Therapeutics
Sarepta Therapeutics is focused on developing first-in-class
RNA-based therapeutics to improve and save the lives of people
affected by serious and life-threatening rare and infectious
diseases. The Company's diverse pipeline includes its lead program
eteplirsen, for Duchenne muscular dystrophy, as well as potential
treatments for some of the world's most lethal infectious diseases.
Sarepta aims to build a leading, independent biotech company
dedicated to translating its RNA-based science into transformational
therapeutics for patients who face significant unmet medical needs.
For more information, please visit us at www.sarepta.com.
Sarepta Investor Contact:
Sarepta Media Contact:
Press spacebar to pause and continue. Press esc to stop.